HIV, HCV Prevalence Rates Among Injection Drug Users in London Increasing, Study Says
November 15, 2004
HIV and hepatitis C virus prevalence rates among injection drug users in the London area are increasing, according to a study published Friday in the online edition of BMJ, Reuters Health reports. Dr. Ali Judd of Imperial College London and colleagues surveyed and tested blood samples from 428 people under age 30 who had used injection drugs for six years or less, according to Reuters Health. The researchers initially found an HCV prevalence of 43.7% and an HIV prevalence of 4.2% among the participants. However, after one year, 53 more participants tested positive for HCV and nine more tested positive for HIV (Reuters Health, 11/12). "Hepatitis C is now spreading at epidemic levels across London, and HIV incidence is worryingly high," the authors said, adding, "There is an urgent need for new and comprehensive programs to tackle this growing problem." The authors said that London now has a higher HCV prevalence among injection drug users than Sydney, Australia, and New York City and a higher HIV prevalence than Amsterdam (Abbas, Reuters, 11/11).
Reaction and Recommendations
Ranbaxy's Removal of AIDS Drugs From WHO-Approved Drug List "Adds Chilly Note" to Fight Against HIV/AIDS, Editorial Says
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.